{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:23:50Z","timestamp":1790522630838,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T00:00:00Z","timestamp":1358294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>\u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a, a 65 amino\u2010acid peptide, has subnanomolar affinity and high selectivity for the human \u03b1<jats:sub>1<\/jats:sub><jats:styled-content style=\"fixed-case\"><jats:sub>A<\/jats:sub><\/jats:styled-content>\u2010adrenoceptor subtype. The purpose of this study was to characterize the pharmacological effects of \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a on prostatic function, both<jats:italic>in vivo<\/jats:italic>and<jats:italic>in vitro<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental Approach<\/jats:title><jats:p>\u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a was tested as an antagonist of adrenaline\u2010induced effects on<jats:styled-content style=\"fixed-case\">COS<\/jats:styled-content>cells transfected with the human \u03b1<jats:sub>1<\/jats:sub><jats:styled-content style=\"fixed-case\"><jats:sub>A<\/jats:sub><\/jats:styled-content>\u2010adrenoceptor as well as on human isolated prostatic adenoma obtained from patients suffering from benign prostatic hyperplasia. Moreover, we compared the effects of \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a and tamsulosin on phenylephrine (<jats:styled-content style=\"fixed-case\">PHE<\/jats:styled-content>)\u2010induced increases in intra\u2010urethral (<jats:styled-content style=\"fixed-case\">IUP<\/jats:styled-content>) and arterial pressures (<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>) in anaesthetized rats, following i.v. or p.o. administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Results<\/jats:title><jats:p>On<jats:styled-content style=\"fixed-case\">COS<\/jats:styled-content>cells expressing human \u03b1<jats:sub>1<\/jats:sub><jats:styled-content style=\"fixed-case\"><jats:sub>A<\/jats:sub><\/jats:styled-content>\u2010adrenoceptors and on human prostatic strips, \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a inhibited adrenaline\u2010 and noradrenaline\u2010induced effects. In anaesthetized rats, \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a and tamsulosin administered i.v. 30\u2009min before<jats:styled-content style=\"fixed-case\">PHE<\/jats:styled-content>significantly antagonized the effects of<jats:styled-content style=\"fixed-case\">PHE<\/jats:styled-content>on<jats:styled-content style=\"fixed-case\">IUP<\/jats:styled-content>. The<jats:styled-content style=\"fixed-case\">pK<jats:sub>B<\/jats:sub><\/jats:styled-content>values for tamsulosin and \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a for this effect were similar. With regards to<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>, \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a only reduced the effect of<jats:styled-content style=\"fixed-case\">PHE<\/jats:styled-content>on AP at the lowest dose tested (10\u2009\u03bcg\u00b7kg<jats:sup>\u22121<\/jats:sup>), whereas tamsulosin significantly reduced<jats:styled-content style=\"fixed-case\">PHE<\/jats:styled-content>effects at doses between 10 and 150\u2009\u03bcg\u00b7kg<jats:sup>\u22121<\/jats:sup>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Implications<\/jats:title><jats:p>\u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a exhibited a relevant effect on<jats:styled-content style=\"fixed-case\">IUP<\/jats:styled-content>and a small effect on<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>. In contrast, tamsulosin antagonized the effects of<jats:styled-content style=\"fixed-case\">PHE<\/jats:styled-content>on both<jats:styled-content style=\"fixed-case\">IUP<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">AP<\/jats:styled-content>. We conclude that \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a is more uroselective than tamsulosin. \u03c1\u2010<jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>a1a is the most selective peptidic antagonist for \u03b1<jats:styled-content style=\"fixed-case\"><jats:sub>1A<\/jats:sub><\/jats:styled-content>\u2010adenoceptors identified to date and could be a new treatment for various urological diseases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1476-5381.2012.02231.x","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T17:52:15Z","timestamp":1348595535000},"page":"618-631","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of \u03c1\u2010<scp>D<\/scp>a1a a peptidic \u03b1<sub>1<\/sub><scp><sub>A<\/sub><\/scp>\u2010adrenoceptor antagonist in human isolated prostatic adenoma and anaesthetized rats"],"prefix":"10.1111","volume":"168","author":[{"given":"S","family":"Palea","sequence":"first","affiliation":[{"name":"UROsphere Facult\u00e9 des Sciences Pharmaceutiques Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Maiga","sequence":"additional","affiliation":[{"name":"Receptors and Channels Team CEA Saclay CEA\/DSV\/iBiTec\u2010S\/SIMOPRO Toxins Gif sur Yvette France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Guilloteau","sequence":"additional","affiliation":[{"name":"UROsphere Facult\u00e9 des Sciences Pharmaceutiques Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rekik","sequence":"additional","affiliation":[{"name":"UROsphere Facult\u00e9 des Sciences Pharmaceutiques Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gu\u00e9rard","sequence":"additional","affiliation":[{"name":"UROsphere Facult\u00e9 des Sciences Pharmaceutiques Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Rouget","sequence":"additional","affiliation":[{"name":"UROsphere Facult\u00e9 des Sciences Pharmaceutiques Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Rischmann","sequence":"additional","affiliation":[{"name":"H\u00f4pital Rangueil Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Botto","sequence":"additional","affiliation":[{"name":"H\u00f4pital Foch Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Camparo","sequence":"additional","affiliation":[{"name":"H\u00f4pital Foch Suresnes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lluel","sequence":"additional","affiliation":[{"name":"UROsphere Facult\u00e9 des Sciences Pharmaceutiques Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Gilles","sequence":"additional","affiliation":[{"name":"Receptors and Channels Team CEA Saclay CEA\/DSV\/iBiTec\u2010S\/SIMOPRO Toxins Gif sur Yvette France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3565(24)35074-8","article-title":"KMD\u20103213, a uroselective and long\u2010acting alpha(1a)\u2010adrenoceptor antagonist, tested in a novel rat model","volume":"291","author":"Akiyama K","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.683"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2005.02.027"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-002-0246-7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000480808","article-title":"Tamsulosin 0.4\u2009mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group","volume":"32","author":"Chapple CR","year":"1997","journal-title":"Eur Urol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01717-X"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.20.13752"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00240-007-0100-x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.04.020"},{"key":"e_1_2_8_11_1","first-page":"107","article-title":"Discriminative and analgesic effects of mu and kappa opioids: in vivo pA2 analysis","volume":"4","author":"Dykstra LA","year":"1988","journal-title":"Psychopharmacol Ser"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.245"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00502-X"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374585-9.00006-2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00872.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(03)00033-0"},{"issue":"4","key":"e_1_2_8_17_1","first-page":"371","article-title":"Alfuzosin reverses bladder overactivity induced by cyclophosphamide in conscious rats","volume":"79","author":"Lluel P","year":"2008","journal-title":"J Urol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00873.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.02.034"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.360"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0022-3565(25)39549-2","article-title":"Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule\u2010controlled responding in rhesus monkeys: antagonism by quadazocine","volume":"267","author":"Negus SS","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-0101(94)90009-4"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700907"},{"key":"e_1_2_8_24_1","first-page":"431","article-title":"Antagonistic effects of alfuzosin on concentration\u2010response curves to phenylephrine and noradrenaline in human prostatic adenoma","volume":"19","author":"Palea S","year":"2000","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.02.023"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0022-3565(24)39060-3","article-title":"An investigation of the uroselective properties of four novel alpha(1a)\u2010adrenergic receptor subtype\u2010selective antagonists","volume":"294","author":"Pulito VL","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00532.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0022-3565(24)38805-6","article-title":"Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin","volume":"296","author":"Sato S","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06092.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn0901-902"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.01.016"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158453.60029.0a"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2012.02231.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2012.02231.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:10:27Z","timestamp":1744197027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2012.02231.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,16]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1476-5381.2012.02231.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02231.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,16]]},"assertion":[{"value":"2012-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}